Kelly Watson
Family · Bolivar, MONPI 1154711265
Payments from drug & device makers
Across 129 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$616
- Braeburn Inc.$291
- Abbott$281
- Lilly USA, LLC$212
- Alkermes, Inc.$157
- Novo Nordisk$132
- plus $837 from 18 others
What the payments were for
- Food & beverage$2,527100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $616 |
| Braeburn Inc. | 8 | $291 |
| Abbott | 14 | $281 |
| Lilly USA, LLC | 13 | $212 |
| Alkermes, Inc. | 5 | $157 |
| Novo Nordisk | 8 | $132 |
| Indivior Inc. | 6 | $127 |
| Amgen | 8 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $97 |
| Exact Sciences | 4 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $67 |
| Gilead | 3 | $49 |
| Eisai Inc. | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 3 | $42 |
| Dexcom, Inc. | 3 | $40 |
| Atricure, Inc. | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Pfizer | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIXADI$123
How this compares
$2,527 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 167 | $26,989 |
| BrixadiBuprenorphine | 25 | $18,068 |
| VivitrolNaltrexone Microspheres | 11 | $17,291 |
| Buprenorphine Hcl | 94 | $5,134 |
| Naltrexone Hcl | 42 | $1,191 |
| Gabapentin | 91 | $760 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $583 |
| Prazosin Hcl | 63 | $581 |
| Bupropion Hcl | 73 | $456 |
| Diclofenac Sodium | 29 | $423 |
| Ondansetron Hcl | 23 | $359 |
| Pantoprazole Sodium | 46 | $294 |
| Quetiapine Fumarate | 66 | $283 |
| Bupropion Hcl SrBupropion Hcl | 36 | $279 |
| Buspirone Hcl | 31 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Braeburn Inc.Brixadi | $291 | $18,06825 claims |
| Alkermes, Inc.Vivitrol | $157 | $17,29111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.
Other family in Bolivar
- Bailey ShunyakovBolivar$27K
- Bethany MartinBolivar$17K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.